Clinical Trial Update: REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial updating REGN2810 plus platinum-based chemotherapy and ipilimumab versus pembrolizumab monotherapy in non-small cell lung cancer was terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Platinum-based doublet chemotherapy
• REGN2810
• ipilimumab (ipilimumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2022-11-16